Recent Therapeutic Advances and Updates
in the Management of MSI-H Colorectal Cancer: A Closer Look at the
Evolving Role of Immunotherapy
A continuing medical education
activity provided by NAMCP and AAMCN
Recent Therapeutic Advances and Updates in the Management of MSI-H
Colorectal Cancer: A Closer Look at the Evolving Role of
Immunotherapy is a two-part webinar series
This is Part 2 of the series focusing on the management and
treatment of colorectal cancer.
This activity is an archive from the webinar held February 26, 2021
This activity is valid from March 1, 2021 to March 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Merck Sharp & Dohme Corp.
Colorectal cancer (CRC) is the development of cancer from the colon
or rectum, due to the abnormal growth of cells that have the ability
to invade or spread to other parts of the body. Excluding skin
cancers, CRC is the third most common cancer diagnosed in both men
and women in the United States. In 2021, it is expected that there
will be 149,500 new cases of colorectal cancer and 52,980 deaths.
When discovered early, CRC is highly treatable. However, when the
disease has spread, treatment becomes much more difficult.
Fortunately, immunotherapy options have become available for
patients with metastatic CRC, particular in MSI-High disease, giving
clinicians and managed care professionals more options in managing
this patient population.
Upon completion of this
activity, participants will be able to:
Identify current unmet clinical and
economic needs in the management of MSI-H colorectal cancer and
evidence-based recommendations for the care of patients with
Use results of MSI/dMMR testing to
determine appropriate management of advanced CRC
Examine recent clinical data on the
safety and efficacy of immune checkpoint inhibitors in the
first-line management of MSI-H colorectal cancer in the first
Examine evidence-based strategies to
monitor for, recognize, and effectively manage potential irAEs
associated with immune checkpoint inhibition in MSI-H colorectal
Identify patients with MSI-H
colorectal cancer who would potentially benefit from
immunotherapies, in first-line settings or beyond
||Richard Kim, MD
Section Chief of GI Medical Oncology, Moffitt Cancer
Associate Professor, Division of Medical Oncology
University of South Florida College of Medicine
|Dr. Kim has
served as a consultant for Merck, Taiho, BMS, and
Pfizer. He has served as a speaker for Lilly and Incyte.
He has served as a researcher for BMS and Eisai. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue